Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News and Views
Nature Biotechnology 26, 769–770 (1 July 2008) | doi:10.1038/nbt0708-769
Hitting the mother lode of tumor angiogenesis
&
Abstract
Despite promising early results, cancer therapy aimed at selective destruction of tumor blood vessels faces several hurdles. Among these is the astronomical expense of chronic intravenous treatment with certain antiangiogenic drugs, which makes long-term therapy impractical for most patients.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
